These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29682098)

  • 21. CT Features of Ovarian Tumors: Defining Key Differences Between Serous Borderline Tumors and Low-Grade Serous Carcinomas.
    Nougaret S; Lakhman Y; Molinari N; Feier D; Scelzo C; Vargas HA; Sosa RE; Hricak H; Soslow RA; Grisham RN; Sala E
    AJR Am J Roentgenol; 2018 Apr; 210(4):918-926. PubMed ID: 29489407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutational spectrum in clinically aggressive low-grade serous carcinoma/serous borderline tumors of the ovary-Clinical significance of BRCA2 gene variants in genomically stable tumors.
    Zhang X; Devins K; Ko EM; Reyes MC; Simpkins F; Drapkin R; Schwartz LE; Yoon JY
    Gynecol Oncol; 2021 Jun; 161(3):762-768. PubMed ID: 33773808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD40 ligand induces RIP1-dependent, necroptosis-like cell death in low-grade serous but not serous borderline ovarian tumor cells.
    Qiu X; Klausen C; Cheng JC; Leung PC
    Cell Death Dis; 2015 Aug; 6(8):e1864. PubMed ID: 26313915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
    Dehari R; Kurman RJ; Logani S; Shih IeM
    Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging in gynecological disease (12): clinical and ultrasound features of invasive and non-invasive malignant serous ovarian tumors.
    Moro F; Baima Poma C; Zannoni GF; Vidal Urbinati A; Pasciuto T; Ludovisi M; Moruzzi MC; Carinelli S; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2017 Dec; 50(6):788-799. PubMed ID: 28101917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
    Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
    Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRAF
    Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
    Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
    Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
    Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nicotinamide N-methyltransferase overexpression may be associated with poor prognosis in ovarian cancer.
    Harmankaya İ; Akar S; Uğraş S; Güler AH; Ezveci H; Aydoğdu M; Çelik Ç
    J Obstet Gynaecol; 2021 Feb; 41(2):248-253. PubMed ID: 32285726
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The molecular pathology of ovarian serous borderline tumors.
    Malpica A; Wong KK
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Idylla KRAS and NRAS mutation test in colorectal cancer tissue.
    Zekri J; Baghdadi MA; Alardati H; Khallaf H; Kabanja JH
    Exp Mol Pathol; 2019 Oct; 110():104270. PubMed ID: 31207216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.
    Murali R; Selenica P; Brown DN; Cheetham RK; Chandramohan R; Claros NL; Bouvier N; Cheng DT; Soslow RA; Weigelt B; McCluggage WG
    Histopathology; 2019 Mar; 74(4):638-650. PubMed ID: 30565721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.
    Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F
    Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Cheng JC; Auersperg N; Leung PC
    Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B
    Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
    Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
    Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.